SOLVE FSHD invests in early-stage companies to ensure a robust pipeline of novel therapies going into clinical trials. We are investing in projects that will grow the number of candidate therapies that make it to clinical trials and get a pipeline built to get more patients into clinical trials and into open-label extensions [programs to provide experimental therapies to patients] while waiting for market [FDA] approval.
Our Approach to Funding
—Facilitate developing therapeutics that maintain or improve muscle function, demonstrated by an improvement in muscle strength.
—Invest in companies to catalyze a cure through disease-modifying treatments.
SOLVE FSHD is focused on supporting:
—The development, validation, and clinical evaluation of biomarkers that predict clinically meaningful outcome measures for use in clinical trials in FSHD.
—Biomarker discovery and Natural History Studies that support drug development efforts.
—Development of pre-clinical systems to increase data quality and success for future therapies advancing to the clinic.
—Development of novel therapies that stop disease progression and/or increase muscle regeneration.
People
- Eva Chin, Executive Director
You last contacted this investor on .